Stock comparison
IDEXX Laboratories
Nektar Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.06B
Sector
Healthcare
NKTR
Nektar Therapeutics
Market cap
$1.3B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | NKTR | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 37D | IDXX |
| Benjamin Graham | 80A | 56D | IDXX |
| Philip Fisher | 75B | 48D | IDXX |
| Peter Lynch | 71B | 3F | IDXX |
| Joel Greenblatt | 83C | 2F | IDXX |
| Charlie Munger | 87A | 39D | IDXX |
| Terry Smith | 84A | 43D | IDXX |
Side-by-side metrics
| Metric | IDXX | NKTR |
|---|---|---|
| Market cap | $44.06B | $1.3B |
| P/E (TTM) | 39.0x | - |
| EV/EBIT | 31.6x | - |
| ROIC (TTM) | 40.66% | -17.17% |
| Gross margin | 62.05% | 99.38% |
| Net margin | 24.63% | -2.84% |
| Revenue CAGR 5y | 7.56% | -14.2% |
| EPS CAGR 5y | 10.79% | - |
| Debt / Equity | 0.7x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Revenue CAGR 5y7.56%vs -14.2%+153%
- ROIC (TTM)40.66%vs -17.17%+142%
- Net margin24.63%vs -2.84%+109%
- Market cap$44.06Bvs $1.3B+97%
NKTR leads on
- EV/EBIT-vs 31.6x+135%
- P/E (TTM)-vs 39.0x+131%
- Debt / Equity0.1xvs 0.7x+79%
- Gross margin99.38%vs 62.05%+38%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.